Holothurians
Holothuroidea
Beche-
Trepang
Halodule
uninervis
Syringodium
istaefolium
stipulacea
REF].The
REF].The
NHPVAs
REF].HPV
REF].However
cytopathologist
REF].In
Borneol
TfR
druggability
angiopep-2
nanotherapeutics
CSssSA
CSssSA
phases:[REF
internal).While
curriculum.7IBL
Aditomo
problems).8In
nondisease
nonillness
REF].The
REF].Studies
REF].The
REF].Our
underrecognition
REF].The
PI3K)/phosphorylation
ERK)/mitogen
CD279
CD274
PDL1
CD)-47
myelocytomatosis
CD-47
CD-47
CD-47
CD-47
SIRPα
REF].The
REF].The
24–36
REF].Another
Cdh2
Cadherin
REF].In
REF].Kinase
temsirolimus
trilaciclib
netarsudil
https://brimr.org/protein-kinase-inhibitors/
1).In
85As2
tomatidine
tomatidine
85As2
Cladiella
Cladiella
pachyclados
REF].Kinase
MEK1/2
binimetinib
cobimetinib
selumetinib
binimetinib
cobimetinib
encorafenib
Selumetinib
bcr
Pheochromocytomas
paragangliomas
PGLs
Pheochromocytomas
PGLs
0.05%–0.1
21.1%–57.6
4%–8
incidentalomas
PGLs
PGLs
25%–30
REF].The
metanephrines
PET)/CT
123I
metaiodobenzylguanidine
123I
PGLs
123I
PGLs
HDACis
HDACis
REF].HDACs
HDACis
HDACis
HDACis
HDACis
HDACis
REF].Abbreviations
HDACis
PGLs
REF].Lipids
Attentionally
REF].In
177,108,695
3,840,223
REF].Currently
REF].Moreover
REF].On
Tajlil
11,382
3,827
7,555
17,278,392
12,347
REF].In
6.2%–9.5

REF].In
Stanish
Silbernagel
carboxyterminal
REF].Research
tendinopathic
REF].A
adulterations
SFCs
SFCs
topolomics
postembryonic
premetamorphic
Lgr5
typhlosole
Lgr5
Premetamorphic
a’-c
postembryonic
15%−20
JWXYS
Hejifang
JWXYS
Angelicae
Danggui
Paeoniae
Baishao
Atractylodis
Macrocephalae
Rhizoma
Baizhu
Bupleuri
Chaihu
Moutan
Mudanpi
Gardeniae
Zhizi
Glycyrrhizae
Gancao
Menthae
Haplocalycis
Bohe
Zingiberis
Rhizoma
Recens
Shengjiang
Danzhi
REF].Fig
1Origin
JWXYS
Xiaoyaosan
Hejifang
JWXYS
Xiaoyaosan
JWXYS
JWXYS
JWXYS
Xiaoyaosan
Hejifang
JWXYS
Xiaoyaosan
JWXYS
JWXYS
JWXYS
JWXYS
https://www.cancer.org/cancer/breast-cancer/about/how-common-is-breast-cancer.html
297,790
55,720
43,700
REF].Therapeutic
medicine.1

antibiotics.9
typhoidal
31.43
Shenzhen,41
SGI1
SGI2
biomechatronic
REF].Targeting
electrocorticogram
HFOs
REF].One
REF].PAC
XPAC(t
xp(t)+1)·sin(2π×13
xp(t
sin(2π×2.5
XAAC(t
|H[xa(t)]|·sin(2π×13
xa(t
V·sin(2π×2.5
XPAC(t
XAAC(t
xa(t
A).This
re)production
territorialism
peptidoglycans
galactofuran
arabinofuran
Mycolic
phthiocerol
dimycocerosates
sulfoglycolipids
REF].During
EpCs
amphipathicity
cationicity
Transcriptomic
REF].Despite
Cov2
REF].The
GLOBOCAN
Akkermansia
muciniphila
Collinsella
aerofaciens
Ruminococcaceae
copri
Alistipes
putredinis
MeA
BNST
BNST
MeA
BNST
REF].More
BNST
hypnopompic
atonia
Adamantidis
REF].NT1
Orx
Orx
Orx
Orx
Orx
Orx
Poryazova
REF].The
REF].Suboptimal
≥16
REF].While
REF].Considering

conceptualises








REF].However
REF].The
FVs
FVs
REF].Use
REF].A
REF].In
REF].Currently
pseudoarthrosis
kyphotic
REF].With
REF].Some
monosegmental
monosegmental
VEGFs
nAMD
neovascularisation
Ranibizumab
Aflibercept
nAMD
REF].Anti
REF].The
treatment’
nAMD
nAMD
REF].Recently
nAMD
REF].MSCs
REF]Despite
MagA
lipocalin-2
protein-2
22–70
REF].Patients
CMNP
REF].Among
CMNP
REF].The
category2,3.There
CMNP
REF].Instrument
IASTM
Cyriax
IASTM
CMNP
MTrPs
REF].Since
IASTM
CMNP
PrEP).Global

REF].Taking
postexposure
dPEP
dPEP
REF].Citizen
Larkwire
proteinopathies
proteostatic
proteinopathies
REF]Kinetic
REF]PolyQ
Rnq1
dhtt
REF]Chaperones
REF]Histone
REF]deubiquitinating
REF]Rab5
REF]Compounds
mHTT
REF]Retinal
polyQ
REF]TOR
NMNAT
REF]Transglutaminases
2022b)Ataxin1
Ser776
Atx2
SCA3
Atx1
Ataxin2
Atx3
ATXN3
Catalytical
Atx3
autoprotective
ATXN3
ATXN3
deubiquitination
Praja1
GGGGCC
Polypeptides
SIGMAR1
2020a)SOD1
Beclin1
P62
SQSTM1
USP7
L3MBTL1
SETD8
USP7
SMAD2
TBPH
Atg7
HSP67Bc
REF].HEXA-018
V)-type
P525L
REF].Glutathionylation
Atg1
Atg8a
Atg18
expressionDysfunctional
formationEctopic
NMNAT
Trx80
Ataxin3
deubiquitinase
Calpain
CG11070
PTK2
2022a)Insulin
REF].Spermidine
LAMP2A
dDOR
IRE1
Atg7
UPS-15
Atg7
BNIP3L
ANKHD1
dLRRK
Olig
Olig1
Olig3
Olig
Olig
Olig1
Olig1
oligodendrogenesis
Olig
pMN
Olig1/2
Olig3
Olig
Olig1/2
Olig
Olig
Gliomas
neuroglial
glioneuronal
1p/19q
1p/19q
codeletion
Gliomas
pilocytic
oligodendrogliomas
oligoastrocytomas
REF].Success
oligoastrocytoma
underdiagnosis
REF].CNS
oligoastrocytomas
glioneuronal
Olig
REF].Adult
1p/19q
codeleted
oligodendrogliomas
GBMs
oligodendrogliomas
1p/19q
codeletion
Oligodendroglial
19q
ATRX
oligodendrogliomas
REF].Because
oligodendrogliomas
oligodendrogliomas
proteolipid
oligodendrogliomas
oligodendrogliomas
oligodendrogliomas
Olig
EF-14
14.7–16.5

temodar
temodar
rGBM
rGBM
REF].There


TTFields
CAR)-T
IL13Rα2
CAR)–engineered

REF].Aside
SurVaxM
CSF1R
CD73
GITR
gasdermin
Gasdermins
gasdermin
gasdermins
DFNB59
DFNB59
DFNB59
gasdermin
GSDMD
gasdermin
REF].GSDMD
caspase-1/4/5
caspase-11
GSDMD
GSDMD
GSDMD
oligomerizes
GSDMD
GSDMD
GSDMD
NOMID
GSDMD
GSDMD
GSDMD
GSDMD
T2DM)[REF

levels.3
phenformin
buformin
guanide

antilipidemic
1.5–4


GLUT-4
lipidemic
lipotoxicity
osteoprotegerin

DLMO
DLMO
zeitgebers
CBTmin
CBTmin
zeitgebers
REF].Many
DSWPD
DSWPD
DSWPD
DSWPD
eveningness
DSWPD
DSWPD
REF].The
DSWPD
PZQ
PZQ
PZQ
PZQ
PZQ
PZQ
PZQ
PZQ
PZQ
PZQ
Reher
REF].Bloom
REF].Evidence
polyradiculoneuropathy
AIDP
AIDP
AIDP
GD1a
GQ1b
GQ1b
MFS.25Inflammatory
Proinflammatory
FoxP-3
Microneedles
REF].A
REF].Several
electrohydrodynamic
REF].This
gynaecologic
REF].Three
28–36
REF].In
Calcaneal
apophysitis
5.8%–22.7
REF].CA
surae
Virtanen13
al5
Heinonem9
CA9
surae
surae
authors5
clubfoot1
REF].Knowledge

Hypermutation
REF].The
REF].As
MPOWER
standard.[REF
1388.2
18,137
5581
REF].Costa
Posttranscriptional
methyladenosine
methyladenosine
m1A
m5C
hydroxymethylcytosine
hmC
N6,2’-O
dimethyladenosine
m6Am
methylguanosine
REF].As
ADAR2
ADAR3
ADAR2
ADAR3
p150
p150
Zα
Zα
Goutières
Dyschromatosis
symmetrica
hereditaria
Gly1007Arg
1(ZBP1
ZBP1
REF].ADAR1
REF].In
standards[REF].In
education[REF
applications[REF].It
provided[REF].Several
audience)[REF].When
users[REF].A
syphilis[REF].In
practices[REF
studies[REF
education[REF].Considering
Cardiomyopathies
30%–50
MYH7
MYBPC3
TNNI3
TNNT2
12%–25
MYH7
TNNT2
Tropomyosin
TPM1
Desmoplakin
RBM20
SCN5A
desmosomal
Plakoglobin
JUP
Plakophilin-2
Desmoglein-2
DSG2
Desmocollin-2
DSC2
Desmin
Filamin
MYBPC3
MYH7
∼60
www.ncbi.nlm.nih.gov/clinvar
cancer‐related
REF].Many
REF].Numerous
sPD
bTMB
REF].The
REF].Sharks
mesopredators
REF].Sharks
Sphyrnidae
Galeocerdo
cuvier
Potamotrygonidae
mtNADH
REF].Understanding
retinovascular
retinovascular
CRAO
CRAO
REF].CRAO
CRAO
cilioretinal
CRAO
arteritic
CRAO
CRAO
cilioretinal
CRAO
arteritic
CRAO
Hayreh
CRAO
CRAO
CRAO
cilioretinal
CRAO
CRAO
Emboli
CRAO
CRAO
CRAO
CRAO
CRAO
CRAO
CRAO
Neovascularization
CRAO
Occlusions
CRAO
CRAO
CRAO
REF].This
CRAO
CRAO
Transversus
TAPB
TAPB
TAPB
TAPB
Transversus
TAPB
TAPB
TAPB
Lap-
TAPB
REF].Currently
TAPB
TAPB
TAPB
REF].The
TAPB
TAPB
TAPB
TAPB
TAPB
TAPB
TAPB
OOCs
fluorescence-
REF].Among
TEER
Glycans
microheterogeneity
TACAs
TACAs
TACAs
TACAs
TACAs
IgGs
TACAs
TACAs
TACAs
Dinutuximab
REF].The
crystallizable
REF].The
dibenzo[b
f]azepine
DSSCs
REF].Dibenzo[b
f]azepine
-oxepine
-thiepine
dibenzo[b
f]heteropines
2).Commercial
dibenzo[b
f]azepine
opipramol
2).Selected
dibenzo[b
f]azepine
skeleton.10,11
Dihydrodibenzo[b
f]azepine
REF].Examples
dihydrodibenzo[b
f]azepine
ligands.4,4'-(5-(Pyridin-2
yl)-10,11
dihydro-5H
dibenzo[b
f]azepine-2,8
diyl)bis(N
diphenylaniline
REF].The
dibenzo[b
f]azepine
dibenzo[b
f]oxepines
azepines
propargylamine
REF].Selective
dibenzo[b
f]oxepine
19).For
dibenzo[b
f]azepine
Kricka
dibenzo[b
f]oxepines
2002.Other
dibenzo[b
f]azepines
-oxepines
dibenzo[b
f]heteropines
1).The
dibenzo[b
f]heteropines
dihydrodibenzo[b
f]heteropines
functionalisation
azepines
oxepines
dibenzo[b
f]heteropines
~46
http://www.fao.org/faostat/en/#home
allotetraploid
RNAome
interactomic
hormonomic
youth1
Cuijpers
2021a
2021b
pharmacotherapies
structural-
REF].Despite
Categorising
integratively
REF].Anticancer

REF].These
REF].The
REF].Pharmacological
erenumab
ditans
gepants
blepharoptosis
REF].In
REF].Migraine
biobehavioral
REF].The
Carabotti
Shreiner
1,25(OH)2D


Akkermansia

D.9

≤26
≤16



Thoracoscopic
Thoracoscopic

Lokiarcheaeota
nanoarchaea
REF].In
~97
extracolonic
~0.1
trophism
REF].Beyond
genotoxins
Faecalibaculum
rodentium
Holdemanella
Erysipelotrichaceae
NFATc3
~0.6
interferonopathies
Goutières
mislocalised
2’3’-cGAMP
ERGIC
polymerises
2’,3’-cyclic
cGAMP
cGAMP
NFkB.
NFkB
REF].Studies
cGAMP
cGAMP
cGAMP
cGAMP
cGAMP
cGAMP
cGAMP
REF].In
scienceArtificial
REF].Alcohol
REF].By
have.[REF
found.[REF
century,[REF
fields.[REF
solving.[REF
problems.[REF
learning.[REF
individuals.[REF
Karakoc
education.[REF]The
learning.[REF
learning,[REF
learning.[REF
century.[REF
knowledge.[REF
subcategories.[REF
skills.[REF
Wahyuni
skills.[REF
Hajrezayi
significant.[REF
skills.[REF
education.[REF
emphasized.[REF
it.[REF
time.[REF
infections.[REF
hepatotropic
HEV).[REF
Hepatitis.[REF
enterically
AVH).[REF
pathway.[REF
anicteric
anicteric.[REF
diseases.[REF]Chronic
130–150
million.[REF
epidemic.[REF
HCC.[REF]HBV
hepatotropism
HCC.[REF
cure.[REF
2021.To
2021.To
”Funnel
”[REF
REF].Globally
REF].Significant
REF].Assessing
REF].Transactional
REF].In
REF].Transactional
REF].In
nanosphere
bio-/chemical
REF].A
n+Δn
Δλ
Δλ/(Δn
linewidths
REF].Fig
1Illustration
n+
Δn
1Illustration
n+
Δn
micro-/nanofabrications
nanohole
nanoring
nanomushroom
linewidths
Benefited
linewidths
linewidths
kWh/(m2·[REF
kWh/(m2
kWh/(m2·[REF
REF].The
Oluseyi
Potchter
REF].Various
REF].Most
22,[REF
orbito
meatal
pTMDs
pTMDs
REF].The
pTMDs
0.16%–0.3

2.5%–5
odontalgia
REF].Despite
REF].The
pTMDs
IRDs
IRDs
IRDs
RPE-65
Adeno
ABCA4
USH2A
CRB1
REF].RNA
udesired
ASOs
ASOs
IRDs
CEP290-
USH2A
IRDs
IRDs
adRP
mirtrons
ADARs
ADAR2
ADARDD
dsRBD
SNVs).Therapeutic
Cas13b
dCas13b
exogeneous
circularisation
ADARs
12.2/100,000
604,000
9.3/100,000
3.6/100,000
8.3/100,000
3.2/100,000
REF].Most
endoscopists
endoscopists
AI)-assisted
Hammersly
SoundOn
Firstory
ABESO
REF].Figure
1Strategies
lossStrategies
lossThe
ultraprocessed
55.970
ultraprocessed
ultraprocessed
ultraprocessed
REF].Low
120,877
ESPEN
ABESO
ABESO
0.5–1.5
births3
NE.The
REF].Many
NCT02811263
NCT03162653
NCT01765218
NCT03913221
NCT03806816
NCT02612155
REF].Collagen
4.8–5.4
REF].Recognizing
Demirhan
Ulca
REF].On
REF].The
Bouligand
Bouligand
REF].Multiscale
biomicrostructures
biofunctional
Bouligand
biostructures
REF].However

30%–50
Kliegman
REF].While
29–78
suprahyoid
thyrohyoid
subglottis
REF].Tongue
Zhengzhai
Zangfu
REF].According
Zangfu
NMSs
0.141
Baschi
REF].Overall
PD.The
75%-85
REF].The
ICIs
ICIs
ORRs
REF].Regulated
HMEs
HDACis
vorinostat
belinostat
panobinostat
HDACis
HDACis
REF].HDACis
properdin
REF].The
sinopulmonary
neisserial
properdin
REF].Even
CH50
LP50
AH50
HIV)/acquired

REF].In
1.19–1.28
guanfacine
REF].Complementary
52–74
REF].Acupuncture
qi”(气
针感
REF].Two
LePine
Harlos
Tangirala
Harlos
REF].Research
REF].Diet
provegetarian

Satija

hPDI
uPDI
embolize
kexin

Resynchronisation
BiV
dyssynchronous
QRSd
AVNA
REF].Despite
resynchronisation
56%–95
LBBP
80%–94
BiV
REF].In
LBBP
LBBP
REF].Acute
REF].Alterations
triacylglycerides
phosphoglycerides
spatholipids
Phosphoglycerides

Sphingolipid
ACAT1
hydroxysterols
miR-33b
SQLE
REF].Therefore
Jinlida
rhizoma
polygonati
rhizoma
atractylodis
lanceae
sophorae
flavescentis
ophiopogon
rehmanniae
polygoni
multiflori
poria
perrin
eupatorium
coptis
anemarrhena
puerariae
lycii
radices
Z20050845
Jinlida
Jinlida
Jinlida
Jinlida
2hPG
Jinlida
miR-27a
Jinlida
Jinlida
T2D.Though
Jinlida
Jinlida
Jinlida
interorgan
REF].The
ϵ-cells
Lakhter


REF].This
interorgan
65–74
75–84
REF].Sodium
transporter-2
SGLT-2is
transporter-2
SGLT-2is
SGLT-2is
HSFA
SGLT-2is
SGLT-2is
REF].Men
SGLT-2is
SGLT-2is
SGLT-2is
SGLT-2is
SGLT-2is
nephroblastoma
nephrogenesis
90%–95
WTs
REF].WT
sarcomatous
NWTS
REF].MicroRNAs
downregulators
3′UTR
deadenylation
REF].As
oncomirs
oncomir
miR-203
DUSP5
FDF2
miR-203
BIRC5
PDHB
REF].Bioinformatic
REF].Interest
REF].MiRNAs
